Strong sequential revenue growth of 40%, accelerating prescriber adoption (23% growth), expanding nursing home penetration (25% growth), successful payer contracts with major PBMs covering 45 million lives, advancement of clinical programs ahead of schedule, patent extensions through 2045, and maintained path to operating profitability in 2027 all indicate solid commercial execution and positive momentum for the company's lead product ZUNVEYL.
Also mentions ACOG
Articles that tag ACOG but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
